Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Japan's epigenetics market is evolving rapidly, with a strong emphasis on AI-driven research and personalized medicine, addressing complex diseases through innovative therapeutic approaches.New Delhi, ...

Christophe Weber will step down as CEO of Takeda next year, the company announced, following a dropoff in its share price ...

The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. | Following some ...

Takeda Pharmaceuticals has named Julie Kim as the first woman to lead the 244-year-old Japanese drugmaker, a rarity in senior ...

TOKYO -- Japan's Takeda Pharmaceutical announced on Thursday that CEO Christophe Weber will step down in June 2026 and be succeeded by current U.S. business head Julie Kim, who would become the ...

Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the ...

Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy ...

Takeda Pharmaceutical Co.’s board has selected Julie Kim, the head of the company’s US unit, to replace Christophe Weber as ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...